- Conditions
- Amyloidosis
- Interventions
- Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 273
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- Custirsen, Docetaxel, Prednisone, Dexamethasone
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Marina del Rey, California + 20 more
- Conditions
- Osteoarthritis
- Interventions
- Bupivacaine, Morphine, Methylprednisolone, Cefazolin, Normal saline, Midazolam, Propofol, Dexamethasone, 8 MHz. Chiba needle, 22 G / 4 inches
- Drug · Device
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Intermediate Uveitis, Posterior Uveitis
- Interventions
- dexamethasone, Sham injection
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cataract
- Interventions
- Dexamethasone, Prednisolone Acetate Ophthalmic
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Huntington Beach, California • Palo Alto, California • Boston, Massachusetts + 6 more
- Conditions
- Cervical Radiculopathy
- Interventions
- Transforaminal ESI with dexamethasone, Transforaminal catheter-targeted ESI with triamcinolone, Dexamethasone Sodium Phosphate 10 MG/ML, Lidocaine, Triamcinolone Acetonide 40mg/mL
- Procedure · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Malignant Neoplasm
- Interventions
- MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Headache
- Interventions
- Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
- Drug · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Retinal Vein Occlusion (RVO), Macular Edema
- Interventions
- Ozurdex implant
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg, Dara-SC 1800 mg, Dexamethasone 20 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Whittier, California + 8 more
- Conditions
- Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
- Interventions
- Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Trigger Finger Disorder
- Interventions
- Dexamethasone Sodium Phosphate, Xylocaine, Sodium Chloride
- Drug
- Lead sponsor
- Kenneth Taylor, M.D.
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 234
- States / cities
- Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
- Interventions
- Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone, Sham
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
- Interventions
- Daratumumab SC, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 31
- States / cities
- San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Kenalog Injectable Product, Decadron Phosphate, Injectable, Epidural Steroid Injection
- Drug · Procedure
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Distal Radius Fracture, Osteoarthritis
- Interventions
- Dexamethasone, Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
- Interventions
- Ozurdex Drug Implant Product
- Drug
- Lead sponsor
- Retina Macula Specialists of Miami, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- North Miami Beach, Florida • South Miami, Florida